Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
Oncotarget2018Vol. 9(9), pp. 8706–8715
Citations Over TimeTop 10% of 2018 papers
Alberto Carretero-González, David Lora, Ismael Ghanem, Jon Zugazagoitia, Daniel Castellano, Juan Manuel Sepúlveda-Sánchez, José A. López-Martín, Luis Paz‐Ares, Guillermo de Velasco
Abstract
In this systematic meta-analysis, anti-PD1/PD-L1 mAbs were associated with a greater overall response rate. Patients with melanoma and those managed in the first line setting seem to have an additional benefit with anti-PD1/PD-L1 mAbs.
Related Papers
- → Success rate of sialendoscopy. A systematic review and meta‐analysis(2023)14 cited
- → Empirical comparison of subgroup effects in conventional and individual patient data meta-analyses(2008)48 cited
- → Chicken Antibodies: A Tool to Avoid Interference by Human Anti-Mouse Antibodies in ELISA After In Vivo Treatment With Murine Monoclonal Antibodies(1992)62 cited
- → Meta-analysis of the changes of peripheral blood regulatory T cell to CD4+ T cell ratio in patients with systemic sclerosis(2017)3 cited
- The polymorphism (Gln261Arg) of 12-lipoxygenase and cancer risk: a meta-analysis.(2015)